MSCI has partnered with Royalty Pharma to launch new indices that aim to capture long-term, cutting edge themes that will disrupt the life sciences, biotechnology and pharmaceutical industry groups, according to a statement from the index provider.
Royalty Pharma, which is listed on the Nasdaq, is the largest buyer of biopharmaceutical royalties and a leading funder of innovation across the biopharmaceutical industry. It will provide expertise on various medical conditions, clinical trials, transformative therapies and technologies that may lead to breakthrough medical treatments that will assist MSCI to design a classification framework and index methodologies.
The initial indices, which are expected to be launched later this year, will measure the performance of companies focused on delivering new and innovative therapeutic treatments related to virology and oncology.
“The Covid-19 pandemic has had a profound impact on all aspects of society and has proven to be an accelerant for long-term structural changes, particularly in the life sciences,” Henry Fernandez, chairman and CEO of MSCI, said in the statement.
“As we have seen during this time, life sciences companies are pivotal to shaping and advancing the healthcare industry and have been critical to the development of approaches for prevention and treatment of diseases.”
